Author

Stefan DiFazio

Henry M. Jackson Foundation

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Ayesha A. ShafiiD· 2 shared Amina Ali· 1 shared Arwa FallatahiD· 1 shared Beatriz GermaniD· 1 shared Cara C. SchaferiD· 1 shared Christopher J. SweeneyiD· 1 shared Christopher M. McNairiD· 1 shared David P. LabbéiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ayesha A. ShafiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Stage-Specific Regulation of DNA Damage Repair by the Circadian Regulator, CRY1, in Prostate Cancer

Arwa Fallatah, Stefan DiFazio, Lakshmi Ravindranath, Thomas Janas, Filippo Pederzoli, Laila N. Scroggins, Noor Abdalla, Orly I. Richter, Sally I. Elsamanoudi, Amina Ali, Jiji Jiang, Isabell A. Sesterhenn, Cara C. Schafer, Massimo F. Loda, Gregory Thomas Chesnut, , Ayesha A. Shafi

This study identifies CRY1 as a stage-specific regulator of DNA damage repair in prostate cancer, showing it promotes NHEJ/BER in hormone-sensitive disease and HR in castration-resistant disease.

bioRxiv · May 21, 2026 · PreprintCancer Biology

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer

Beatriz German, Katherine L. Morel, Teia Noel, Nadia Boufaied, Deborah L. Burkhart, Sujun Chen, Felipe Segato Dezem, Xintao Qiu, Henry W. Long, Stefan DiFazio, Sylvan C. Baca, Ayesha A. Shafi, Matthew L. Freedman, Himisha Beltran, Christopher J. Sweeney, , Leigh Ellis

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

bioRxiv · Aug 7, 2025 · PreprintCancer Biology